CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 74-89% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money. Please refer to our Risk Disclosure Statement
Open platformOpen platform

Eyconis to Participate in Upcoming Investor Conferences

By GlobeNewswire

REDWOOD CITY, Calif., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Eyconis, Inc., a clinical-stage biotechnology company advancing next-generation, long-acting ophthalmic therapeutics, today announced that members of its management team will participate in one-on-one investor meetings at the following upcoming investor conferences:

Wells Fargo Virtual Private Biopharma Symposium
Date: November 4, 2026
Location: Virtual

Stifel 2026 Healthcare Conference
Date: November 10, 2026
Location: New York City

LifeSci Capital Conference
Date: November 16, 2026
Location: London

UBS Global Biopharma Conference
Date: November 17, 2026
Location: London

Piper Sandler 38th Annual Healthcare Conference
Date: December 1, 2026
Location: New York City

Investors interested in meeting with Eyconis should contact their representative at the applicable conference host.

About Eyconis

Eyconis, a clinical-stage biotechnology company, is advancing next-generation, long-acting ophthalmic therapeutics. Through an exclusive worldwide license in ophthalmology from Ascendis Pharma, Eyconis is utilizing the commercially validated TransCon® technology platform to develop therapies that have the potential to reduce treatment burden, optimize disease control, and improve visual outcomes in people with serious eye disease. Eyconis’ lead program, EYC-0305, is being developed as a long-acting anti-VEGF therapy for wet age-related macular degeneration, with potential applicability across other retinal diseases including diabetic macular edema, diabetic retinopathy, and retinal vein occlusion. EYC-0305 is currently being evaluated in OVERTURE, a Phase 1b/2a clinical trial in treatment-naïve patients with wet age-related macular degeneration. Beyond EYC-0305, Eyconis is developing a broader pipeline of long-acting therapies across other ophthalmic indications with significant unmet need. For more information, visit www.eyconis.com.

Ascendis Pharma and TransCon are trademarks owned by the Ascendis Pharma group.

Contacts

Investor Contact
Chris Brinzey
ICR Healthcare
chris.brinzey@icrhealthcare.com

Media Contact
Ben Shannon
ICR Healthcare
ben.shannon@icrhealthcare.com


Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk